PDCD1 and neoplasm: Interestingly, these resistant cells also showed poor response to anti-PD-1 antibody, and a combination of AXL inhibitor BGB324 and anti-PD-1 antibody suppressed in vivo tumor growth more robustly than each agent alone [53].